Are Salt Alternatives Dangerous for People With Kidney Disease?

Posted from: https://www.everydayhealth.com/kidney-diseases/are-salt-alternatives-dangerous-for-people-with-kidney-disease/

The U.S. Food and Drug Administration (FDA) announced a proposed rule earlier this month that would allow food manufacturers to use salt substitutes in place of the real thing. The public health measure is aimed at reducing the amount of added sodium in foods. About 90 percent of Americans ages 2 and up consume too much salt, according to the Centers for Disease Control and Prevention (CDC) , which contributes to the high burden of chronic disease seen across the nation. One of the proposed substitutes is potassium chloride, also known as potassium salt. The natural alternative to sodium provides a similar flavor without the negative effects of sodium. But advocates for people with kidney disease warn the move to add potassium to food could be dangerous — and even fatal — for people with chronic kidney disease . The American Association of Kidney Patients (AAKP), the Academy of Nutrition and Dietetics (the Academy), and the National Kidney Foundation (NKF) issued a statement August 8 , soon after the FDA made its announcement, stating their concerns and pushing against the proposed rule. While they applauded the FDA’s effort to reduce sodium in packaged foods, “We must balance population health goals and the acute needs of an already medically complex population,” the organizations wrote. Kidney Disease Prevents the Body From Excreting Potassium An estimated 37 million American adults, or about 15 percent of the population, live with chronic kidney disease, a condition that disproportionately impacts people of color, according to the CDC . Black Americans make up roughly 13 percent of the U.S. population, but account for 35 percent of people with kidney failure. Hispanic Americans are also nearly 1.3 times more likely to develop kidney failure than non-Hispanic Americans, and the rate of kidney failure among this population has gone up by 70 percent since 2000, the National Institutes of Health (NIH) reports . Many people with chronic kidney disease, including those with kidney failure, cannot excrete potassium normally. If these people eat high amounts of potassium, the mineral can accumulate in their blood. Elevated levels of potassium in the blood, a condition called hyperkalemia , can cause abnormal heart rhythms and even sudden cardiac death. “Given the very high estimates of those who are unaware they have compromised kidney function and the clinical consequences of hyperkalemia, adding ‘hidden potassium’ in the form of potassium chloride substitutes to the American diet is a risk that should not be taken,” the AAKP statement said. But David Goldfarb, MD , the clinical chief of nephrology at NYU Langone Health in New York City, says the proposed changes likely will only affect people who are being treated for severe kidney disease, and even then, the effects will likely be modest. People who have decreased kidney function and are taking angiotensin-converting enzyme (ACE) inhibitors, angiotensin 2 receptor blockers (ARBs), or another drug called spironolactone, could be affected by increased potassium in foods, since they make it more difficult for a person’s body to excrete potassium — but there are medications that can prevent this. These secondary drugs work by binding to potassium in the intestines, which reduces potassium in the blood. According to Dr. Goldfarb, these medications are already commonly prescribed to people with chronic kidney disease who are on medications that can make too much potassium a dangerous issue. “These people also would have their potassium checked on a regular basis regardless of this FDA change,” he says. Population Benefits Could Outweigh Small Risk of Harm — but People With Kidney Disease Should Be Monitored Goldfarb argued the change would likely do more good than harm. “People recognize that sodium is adverse and that people have to limit their salt intake, and that’s true especially for people with conditions such as chronic kidney disease, bone disease, and high blood pressure,” he says. Too much salt can actually be a contributing factor that causes kidney disease, according to the National Kidney Foundation . It also causes high blood pressure, stroke, and heart disease, the No. 1 killer worldwide. Salt Substitutes May Lower the Risk of Cardiovascular Disease and Death A randomized clinical trial published in the New England Journal of Medicine in 2021 tested the effects of salt versus a potassium-based salt substitute in 600 villages in rural China. The study included nearly 21,000 people who were all ages 60 or older, and nearly all had a history of stroke, hypertension, or both. Half the participants used a salt substitute that was 75 percent sodium chloride (table salt) and 25 percent potassium chloride. The other half used regular salt. The researchers followed up after about five years and found that people in the salt substitute group had lower rates of stroke, major cardiovascular events, and death from any cause. A major caveat of the study, though, was that it excluded people who had kidney disease and were on medications that made them more susceptible to hyperkalemia — so the study doesn’t give insights on whether or not the extra potassium would impact this population. Although he’s in support of the rule, Goldfarb does not dismiss its potential impact, and stresses that it’s important for people with chronic kidney disease who are on medications that make them more susceptible to hyperkalemia to be monitored. “There’s a possibility that a modest amount of potassium would be safe for people with kidney disease, but there’s a border to that,” he said, noting that it’s likely potassium levels would stay relatively low in foods that contain salt alternatives, since it typically replaces some, but not all, of the salt. “The amount of potassium that could be used as a salt substitute is relatively small and not necessarily dangerous even to people with kidney disease.”

For the First Time, Microplastics Detected in Human Heart Tissue

Posted from: https://www.everydayhealth.com/public-health/for-the-first-time-microplastics-detected-in-human-heart-tissue/

Minute particles of plastic (called microplastics) are everywhere. They’ve been found in our water, food, and the air we breathe, according to a 2021 scientific review . Just a year later, another study found microplastics in the human bloodstream. Now, in what researchers are calling a first, microplastics have been detected in the heart tissues of individuals who underwent cardiac surgery. Based on heart tissue samples collected from 15 people who underwent heart operations, scientists discovered tens to thousands of individual microplastic pieces in most tissue samples analyzed — although the amounts and materials varied between participants. “The detection of microplastics in vivo [in the living body] is alarming, and more studies are necessary to investigate how the microparticles enter the cardiac tissues and the potential effects of microplastics on long-term prognosis after cardiac surgery,” wrote study author Xiubin Yang, MD, in the department of cardiovascular surgery at Beijing Anzhen Hospital in China, and colleagues. As published in the American Chemical Society journal Environmental Science and Technology , Dr. Yang and his team, using direct infrared imaging, identified 20 to 500 micrometer-wide particles made from eight types of plastic. The scientists also found plastic particles in blood samples collected from participants. They added that “microplastics are highly likely to distribute in various organs throughout the body.” Plastic Particles May Be Introduced During Surgery The study authors emphasized that invasive medical procedures may be an overlooked route of microplastics exposure. A fraction of the plastic pieces (0.34 percent) identified had a diameter too large to likely enter the body through inhalation or ingestion, according to the analysis. This indicated that the heart operation itself may “permit direct access of microplastics to the bloodstream and tissues.” The researchers cited previous scientific investigation showing that microplastics have been detected in the air in operating rooms and could directly enter a patient whose organs are exposed to the air during surgery. They indicated that large particles may also come from equipment and materials used in a heart operation, including surgical incision protective film, intravenous therapy bags, tubing, and syringes. The types of plastics detected might also offer evidence that microplastics could be introduced during surgery. “I was very surprised that the two big heavy hitters of plastic pollution in the environment — polyethylene and polypropylene — were relatively very small in this study,” says Christopher Reddy, PhD , an expert on plastic pollution and a senior scientist in the department of marine chemistry and geochemistry at the Woods Hole Oceanographic Institution in Falmouth, Massachusetts, who was not involved in the study. “Three-quarters of all the plastics in this research were PET, polyethylene terephthalate [commonly used in plastic water bottles].” Although particles may be leaching from plastic materials related to surgery, Timothy O’Toole, PhD , an associate professor of medicine at the University of Louisville School of Medicine in Kentucky, who has analyzed how microplastics may raise the risk of heart disease, suggests that microplastic contamination is so common now that these tiny pieces may also be entering heart tissue through the environment. “Previous studies have shown that microplastics have been found in a number of human tissue samples — blood, lungs, breast milk, feces — which are believed to come from food, water supplies, or by inhalation,” says Dr. O’Toole, who was not involved in this research. “The importance of this study seems to be that routine medical procedures may introduce them as well.” Is It Dangerous for Microplastics to Be in the Body? No matter how microplastics get into the body, some scientific evidence has highlighted potential health hazards. An analysis published in the Journal of Hazardous Materials , looking at 17 previous reports involving the impact of microplastics on human cells, determined that ingesting microplastics may contribute to cell death, allergic response, and damage to cell walls. In a mouse study published in 2021 in the American Heart Association journal Circulation , O’Toole and collaborators concluded that microplastics may be an unrecognized risk factor for atherosclerosis (the narrowing and hardening of arteries) and cardiovascular disease. “Chronic exposure may also lead to health problems associated with inflammation, such as diabetes or liver disease,” says O’Toole. “The danger to one’s health may depend on how long these particles have been in the heart. If just introduced during the procedure, microplastics are probably not of immediate concern, but they may cause long-term problems if not cleared.” While the health implications are still unknown, and limiting exposure in our modern society may be difficult, avoiding plastic packaging and plastic products when possible might reduce some risk. Dr. Reddy stresses that much more research is needed. He points out that this study was very small, involving just 15 individuals from China, and that three-quarters of the PET particles identified came from just one person. “This is a relatively limited amount of samples by one lab group,” he says. “The big question is still, ‘What are the negative effects from exposure?’ At this stage, if I knew anybody was having cardiac surgery, I wouldn’t be worried about the potential issues of plastic getting in the body.”

Overcoming “Mom Guilt” as a Woman with Crohn’s Disease

Posted from: https://www.everydayhealth.com/crohns-disease/overcoming-mom-guilt/

If you’re a mom — even a mom without serious health issues — you’ve probably experienced the feeling of “mom guilt” before. As the name implies, “mom guilt” is a term used to describe the guilt many caregivers feel when they don’t meet their expectations as a parent, according to Cleveland Clinic . When you’re a parent and have a chronic illness, there’s an extra layer of complexity to this emotion. For example, there’s a popular saying: “There’s no sick days for mamas.” But, as someone with Crohn’s disease and a mother of three children — ages 2, 4, and 6 — there are certainly days when I am sick, which can cut into my family time. Still, I don’t let those feelings of guilt consume me. Here’s how I overcome mom guilt while managing my chronic illness. Set Realistic Expectations for Yourself One of the most challenging aspects of living with Crohn’s disease is the unpredictability of the condition. There’s no telling how you’re going to feel each day. As a parent, this can be especially stressful, because your family depends on you to take care of their needs, no matter how you feel. All too often, we push ourselves and put our own needs last. Luckily, I’ve been in remission the whole time I’ve been a mom — my first was born in 2017 — but that doesn’t mean I don’t experience pain, fatigue, urgency, and a laundry list of unpleasant symptoms of Crohn’s disease. Through the years I’ve learned that having a low-key day with my kids and not pushing myself to the extreme is a win-win for everyone involved. If I’m feeling fatigued and it’s a beautiful day, I often feel guilty about not capitalizing on the weather and taking my little ones on an adventure, but I also know to listen to my body. Sometimes, that means having a movie day and snuggling on the couch, and that’s okay. Don’t Compare Yourself to Others on Social Media Social media can be a huge point of connection for people with chronic illness, by allowing us to feel seen with our sometimes challenging realities. But, it can also highlight how we may not be measuring up to other parents, who are taking their kids on trips and seem to be doing all the things, all the time, with their families. While it may appear other families are thriving 100 percent of the time and never bored (or even at home), remember that social media is everyone’s highlight reel. We all do it. We’re not showing the moments that upset us, such as the tantrums being thrown to get out the door or the kids fighting in the car or the snack being mushed into the floor of the van. We’re posting pictures and videos of our kids smiling and loving life with one another. Be mindful of this, and know that just being present for your child makes them feel loved, whether that’s at home or on an action-packed day out and about. Prioritize Self-Care and Be Intentional About It Self-care often feels like a buzzword that can feel impossible when you’re drowning in mom duties 24/7. Recognize that taking care of your own health is crucial for both you and your family. Just as your child’s well-being is always top of mind, make sure you take time for yourself. This can be something as simple as going for a walk, following a skin-care routine, taking a bath, reading a book, or waking up a little early to enjoy a cup of coffee in peace and quiet. Try to set aside at least 20 to 30 minutes a day for yourself to do something that brings you joy. Accept Support and Ask for Help Don’t be afraid to lean on your support system. I struggle with asking for help myself, but when I receive it, it makes a big difference in my ability to juggle Crohn’s disease and motherhood. Rely on family, friends, and trusted caregivers to assist with childcare when needed. Remember that reaching out for support is not a sign of weakness but an act of self-care. One of the best parts of social media is connecting with other parents who live with a chronic illness and understand how challenging it is. We’re all in this together, and it’s empowering to talk with others, encourage one another, and share what’s worked on the difficult days. Some of my favorite online groups are IBD Moms , Mamas Facing Forward , and IBD Social Circle . Have Honest Conversations With Your Children Try to be open with your kids about your limitations, even when you aren’t feeling your best or are trying to smile through it. I tell them Mommy’s tummy hurts or let them know when I need to lie down. Being open with my kids has instilled empathy and compassion in them, starting from a young age. I often don’t even need to tell them when I’m unwell; they can recognize it from the look on my face or when I grasp my abdomen or when I need to run to the bathroom countless times. It does not make you a weak parent to admit you’re struggling. If anything, this teaches your kids that it’s okay to not be okay. Reassure your children that how you’re feeling doesn’t diminish your love for them. It just highlights the importance of taking care of yourself, which is a valuable lesson to teach them. Treasure What You Have Being a parent takes a lot, regardless of whether you have health problems. For someone with inflammatory bowel disease, it’s about finding balance between taking care of yourself and taking care of your children. It’s about making sure you’re managing your disease to the best of your ability, so you can be present and at home as much as possible. There’s no telling when that next hospital stay will be, so soak up the feel-good days and the beautiful moments with your children. Just as you’ll blink and years will have passed on your health journey, so will the time you have with your children. Give yourself grace and remember that you are giving it your all, despite the uphill battle you’re facing with a challenging health condition. Look at pregnancy and parenthood and all that you’re capable of, despite your disease, and allow that to give you a renewed sense of love and appreciation for your body. Rather than dwelling on what you feel guilty about, focus on the positive aspects of your parenting. And, most of all, be kind to yourself, and remind yourself that it’s okay to prioritize your health.

Newly Approved Izervay Expands Treatment Options for Geographic Atrophy

Posted from: https://www.everydayhealth.com/macular-degeneration/izervay-expands-treatment-options-for-geographic-atrophy/

The U.S. Food and Drug Administration (FDA) has approved a new drug that slows the progression of an advanced form of age-related macular degeneration (AMD) that was untreatable before 2023. The August 4 FDA go-ahead for the Iveric Bio drug Izervay (avacincaptad pegol intravitreal solution) followed extensive clinical trials in which monthly 2 milligram (mg) in-eye injections of the medication significantly reduced the damage done by geographic atrophy (GA), or advanced dry AMD , for most study participants. The makers of Izervay state that it is the only approved geographic atrophy treatment that can achieve a statistically significant reduction in the rate of GA progression at the 12-month endpoint. Earlier in 2023, the FDA approved the drug Syfovre (pegcetacoplan) , developed by Apellis Pharmaceuticals , as the first-ever treatment for geographic atrophy. What Is Geographic Atrophy? Also called “advanced dry AMD,” geographic atrophy can develop after dry particles of biological debris, or drusen, build up in the retina early in the disease. As these protein and lipid clumps accumulate, they can irritate the cells of the macula, which is the part of the light-sensing retina responsible for delivering the sharpest, straight-ahead sight. The disease can eventually transition into the “wet” stage of AMD, where dysfunctional blood vessels proliferate in the retina, leaking fluid and blood that gradually snuffs out critical photoreceptor cells, leading to irreversible loss of sight — though geographic atrophy does not always progress to wet AMD . New Drugs Help Fill a Significant Treatment Gap The latest FDA nod effectively doubles the pharmaceutical options available for a serious, vision-threatening condition for which physicians previously resorted to mere watchful waiting. “This latest drug approval is an extremely positive development, especially since as recently as a year ago, there was no hope and no options for people with GA,” says Jeff Todd , the president and CEO of Prevent Blindness , a vision health nonprofit. At least a million Americans and eight million people worldwide are currently diagnosed with the disease, according to the Cleveland Clinic . Some clinicians, though, believe the reach of geographic atrophy is far greater than the statistics suggest. “We estimate that about a million and a half Americans have GA, but that 75 percent of people with the disease are likely to be undiagnosed, leading to a huge unmet need among people who are typically age 65 and older,” says Chris Simms , the senior vice president and chief commercial officer of Iveric Bio. The Parsippany, New Jersey–based company warns that 66 percent of people with geographic atrophy can become partially or severely visually impaired when the condition goes undetected. Clinical Trials Show Slowing of Disease Progression Iveric’s GATHER1 phase 2/3 clinical trial achieved a 35 percent reduction in geographic atrophy progression, and GATHER2 phase 3 trial nearly an 18 percent reduction in progression, both generating positive results as early as six months into the testing period, according to commentary in AJMC . The randomized, double-masked, multicenter trials enrolled more than 700 participants. Side effects were reported by fewer than 5 percent of the subjects and included bleeding beneath the clear lining of the eye, increased eye pressure, blurred vision, and the development of neovascular age-related macular degeneration, or wet AMD. Both Izervay and Syfovre inhibit the overactivation of one of the roughly 50 biochemical compounds found in the complement system, which mobilizes proteins to battle invading pathogens. Izervay specifically targets the runaway damage caused by the C5 protein, which can worsen the maplike lesions that develop on the scarred retina. These distinguishing marks give geographic atrophy its name. Side Effects Are a Possibility, but the Safety Profile Is Solid While retinologists hail both new drugs for opening the expanding the frontier in AMD treatment, some clinicians are tempering their optimism with caution. Among them is Peter A. Campochiaro, MD , the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute of Johns Hopkins Medicine in Baltimore, who fears that treatments may occasionally create complications that mimic the disease itself. “Some Syfovre patients developed severe inflammation, retinal vasculitis, and loss of vision after receiving the drug, which has a major impact on its risk-benefit ratio,” says Dr. Campochiaro. Such side effects are rare. Iveric’s Simms is confident that Izervay’s safety and efficacy profile is solid, and that side effects are extremely infrequent and treatable if they do occur. “We like to reiterate that over the 12-month period (of the study) … the drug slowed the loss of photoreceptors and disease progression with a rate of GA reduction of up to 35 percent at end of the first year of treatment,” says Simms. As clinical trials continue, Iveric expects to share updates about the drug’s effects beyond the 12-month mark. Those findings are expected near the end of 2023. The drug itself will be available in doctors’ offices by mid-September.

A Therapist Speaks: Is Wegovy Right for Psychiatric Medication-Related Weight Gain?

Posted from: https://www.everydayhealth.com/columns/a-therapist-speaks/is-wegovy-right-for-psychiatric-medication-related-weight-gain/

Since the U.S. Food and Drug Administration (FDA) approved it in June of 2021, Wegovy (semaglutide) has taken weight management by storm. And, it’s no wonder that it did. A large randomized-controlled trial showed those who took Wegovy lost 14.9 percent of their bodyweight (compared with just 2.4 percent in those who took the placebo), making Wegovy one of the most effective weight loss medications on the market. And, with weight gain and diabetes being such a common side effect of psychiatric medications, it is also no wonder that psychiatrists are increasingly considering if Wegovy and other similar prescription weight loss drugs in development (like Mounjaro ) are right for their patients’ psychiatric medication–related weight gain. Why wouldn’t it be right for these patients? As a psychiatrist who treats individuals with a range of mental health conditions, prescribing the new weight loss drugs for psychotropic-related weight gain (“psychotropic” is the term for psychiatric medications) gives me pause. That doesn’t mean these drugs should not be prescribed to individuals with mental illnesses, but there are a few important things to keep in mind — for both patients and clinicians — to determine if they are appropriate. The first is that many mental health issues counted as exclusion criteria in the studies that led to Wegovy’s FDA approval. For example, history of major depressive disorder within two years of the study, diagnosis of any other severe psychiatric disorder such as schizophrenia and bipolar disorder, as well as any history of suicide attempt and recent suicidal behavior were all listed as exclusion criteria Wegovy’s largest trial . So we don’t know how this medication will interact with these diseases, both in terms of the efficacy of the medication in this population as well as the adverse impact it may have on psychiatric symptoms. As a psychiatrist, it pains me that many clinical trials use psychiatric illnesses as exclusion criteria when selecting study participants. This practice further marginalizes those with mental illness and could contribute to the already wide health gap that exists between those with mental illness and those without. There is a large body of research that shows those with mental illnesses are more likely to struggle with weight and die prematurely from weight-related cardiometabolic illnesses, like heart disease and stroke, than the general population. If tools like Wegovy and other prescription weight loss drugs could help prevent some of these morbidities, the lack of data showing their safety and effectiveness in this population (which is what gives me confidence as a provider in prescribing that drug) is a missed opportunity. People with mental illness deserve to have all of the tools at their disposal that others have to prevent these outcomes. 4 Questions to Discuss With Your Doctor That being said, because of the absence of studies involving Wegovy and people with mental illnesses, there are a number of questions patients should discuss with their doctor to determine if the medication is an appropriate tool to help manage their psychiatric medication–related weight gain. 1. What Does the Evidence Show and How Does It Apply to Me? Not only has Wegovy not been studied in those with serious mental illness, it also has not been studied specifically for psychotropic-related weight gain. This is very important for two big reasons. The first is that we cannot be as certain of Wegovy’s efficacy. We don’t understand all of the mechanisms, but we know psychiatric medications can impact metabolism and weight in various ways, according to research . Although a few case studies seem to suggest Wegovy is still somewhat effective at counteracting these mechanisms, we don’t know if it will be as effective in this setting. The second is that we also cannot be as certain of Wegovy’s side effects. More specifically, we don’t know what impact Wegovy could have on existing psychiatric symptoms. Additionally, although none of the clinical trials of Wegovy demonstrated an increase in suicidal thoughts, the link is now being researched further as a number of reports of suicidal thoughts from people taking Wegovy have emerged. This means the risk-benefit discussion regarding Wegovy is more difficult when it comes to someone with psychiatric medication–related weight gain because there are more unknowns. This does not mean the medication cannot be used, but, as a patient, you should be informed of these unknowns. You should also be in close communication with your provider to determine if the medication is benefiting you and so they know what side effects you are experiencing. 2. What Diet and Exercise Behaviors Will I Need to Change? It is important to note that the FDA approved using Wegovy in combination with diet change and exercise. Lifestyle change plays a significant role in weight management, even when alone it is not enough. Research already shows people with mental illnesses are less likely to receive lifestyle counseling to their detriment. If your doctor is talking to you about weight loss medications, including Wegovy, make sure they are also giving you information and counseling on lifestyle changes that can help support you in your health goals. As previously said, those with mental illness deserve to have all the tools others have in preventing disease — and that includes lifestyle counseling. 3. How Will I Get Appropriate Follow-Up Care? Psychiatrists have been prescribing Metformin, another medication, for medication-related weight gain for a number of years. Nevertheless, psychiatrists are not endocrinologists, and this is not our specialty. Wegovy is a much newer medication, and there are a number of important side effects to consider, including the potential risk of certain types of thyroid tumors, pancreatitis, gallstones, and eye issues. It is essential that a person be counseled on all these side effects and followed-up to ensure they are not developing them. Ideally, a psychiatrist would refer their patient to a specialist for Wegovy. However, this is not always realistic. In this case, it is important that the psychiatrist is in close communication with an endocrinologist, obesity medicine doctor, or other specialist in this area, and if possible, that the patient is also followed by that specialist, even if they see their psychiatrist more often. This may mean that there are more appropriate clinical settings for Wegovy to be prescribed to someone for psychiatric medication–related weight gain than others. For example, it may be best to see a psychiatrist in person and in a clinic or office that is associated with other medical specialities, rather than in a siloed telehealth private practice setting in which physical examination and follow-up is more challenging 4. How Much Is the Drug Going to Cost Me? There have already been issues obtaining Wegovy due to supply issues, according to Novo Nordisk , the pharmaceutical company that makes the drug. Further, it’s an expensive medication, and it’s unclear if insurance companies will cover what may be considered “off-label” uses (such as they might consider using the drug to mitigate psychotropic-related weight gain). This has led to the creation of compounded versions of the drug , which the FDA has warned against due to safety and efficacy concerns. To make sure patients are not tempted by these less safe and less effective options, doctors should ensure patients have access to the medication before prescribing. Patients should also have a clear understanding of how much it will cost them and of any availability issues. If cost or availability make it an unrealistic choice, alternatives should be offered in the interim.

Early-Onset Cancers Are on the Rise Among People Under 50

Posted from: https://www.everydayhealth.com/colon-cancer/early-onset-cancers-are-on-the-rise-among-people-under-50/

Cancer rates in people under 50 years old are rising, according to a new study published today in JAMA Network Open . Breast cancer accounted for the highest number of cancer cases in younger people, and gastrointestinal cancers, including colon cancer , saw the largest percentage increase of any type of cancer. Researchers also found that during the same time period, 2010 to 2019, cancer rates among people 50 and older have gone down. Healthcare professionals need to know about the increasing incidence of early-onset cancer, the authors wrote, and “investigations for possible tumors need to be considered when clinically appropriate, even in patients younger than 50 years.” Suneel Kamath, MD , a hematologist, medical oncologist, and assistant professor of medicine at Cleveland Clinic in Ohio, agrees. “Many of the people I see told me that they saw several different doctors for many months for the same symptoms, and nobody thought of cancer. The thought was, ‘You’re too young to have cancer, so it can’t be that,’” explains Dr. Kamath, who was not involved in the research. Not only is the study important to build awareness so that diagnoses will not be missed, but it could also lead to more funding for research to “get to the bottom of why this is happening,” Kamath says. Early-Onset Cancer Increased in Women but Declined in Men The study used data from 2010 to 2019 from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program to analyze the incidence of early-onset cancers overall and in different organ systems, as well as patterns according to sex, age group, and race and ethnicity. The SEER database that collects data on cancer cases from various locations and sources throughout the United States. Over the 10-year period, a total of 562,145 people with early-onset cancer (cancer in people under 50 years old) were identified, and 62.5 percent were female. Overall, there was a 0.74 percent increase during the study period, with early-onset cancers in women increasing by 4.4 percent but declining by 4.9 percent among men. The increases seen among younger women were likely driven by the rise in cancers of the breast and uterus, wrote the authors. In 2019 alone, the highest number of early-onset cases were breast cancers, with 12,649 cases, followed by thyroid cancer, with 5,869 cases. GI Cancers the Fastest Growing Early-Onset Cancer From 2010 to 2019, rates of gastrointestinal cancers were the fastest-rising among all early-onset cancers, increasing by almost 15 percent. In addition to colon cancer, cancers of the appendix, bile ducts in the liver, and pancreas had the fastest growth rates, according to the study results. By age, the increase in incidence was greatest in people between 30 and 39 years old. Investigators found that early-onset cases rose 32 percent among people of Asian or Pacific Island background and nearly 28 percent among Hispanic people over the study period. Cancer rates fell nearly 12 percent among white people and 5 percent among Black Americans, though researchers note there could have been underreporting or underdiagnosis in underserved populations. “I think this is a really important article in a growing literature really showing that cancer is increasingly in the young. There just seems to be this rise in a number of different cancers and people even in their twenties and thirties,” says Kamath. Not only will these findings build a greater awareness that cancer in younger people is on the rise, but it could also help identify groups at higher risk, says Kamath. “For example, people of Asian descent or Hispanic descent where there was the biggest spike may benefit from increased screening,” he says. Early Onset Cancer Is Often More Difficult to Treat Cancer in people under 50 tends to be more difficult to treat, and a big part of that is because these cancers are diagnosed at very late stages, so outcomes tend to be worse, says Kamath. “The cancer diagnosis in a young adult is more devastating, when life is supposed to be full of great excitement and expectations, such as career goals and family life,” says Ning Jin, MD , a gastrointestinal medical oncologist with The Ohio State University Comprehensive Cancer Center in Columbus, who was not involved in the research. People under 50 may have more financial stress and difficulty in balancing work, life, and medical treatment, Dr. Jin explains. “They often need to deal with acute and long-term side effects from treatment, including the pain and bowel dysfunction. If patients require radiation treatment for their rectal cancer, there will be concerns for fertility, sexual dysfunction, and colostomy management,” she adds. In many cases, younger people have a delay in diagnosis — and therefore a delay in treatment — that can increase the likelihood of poorer outcomes, says Kamath. Lifestyle and Early Exposure to Antibiotics May Play a Role in Cancers in Younger Adults More research is needed to find out why cancer is on the rise in younger adults and in certain groups, according to the authors. It could be related to lifestyle changes, such as the typical Western diet ( more red meat and less fiber ), and food additives , says Lin. There’s also data to suggest that antibiotic use, especially early in life, could play a role, says Kamath. “There does seem to be this birth cohort effect, where people born in a certain time frame — the 1980s until the early 2000s — may be the most impacted.” During this period, the overprescribing of antibiotics may have had long-term impact on the microbiome and may be related to more cancer onset later in life, he says. Why the Decrease in Cancer Rates in Older Adults? It may be that screenings such as mammograms or colonoscopies could be helping reduce the cancer incidence in some cases, says Kamath. “If you think about mammograms for example, if you detect a precancerous lump before it turns into cancer and it gets removed, you can stop a cancer from happening. In a colonoscopy, if polyps are identified and removed, you’re actually stopping people from ever developing colon cancer,” he says. And although screening is certainly making a dent in reducing the number of older adults with cancer, some of the reduction is caused by the people who would have developed cancer in their fifties and sixties getting it earlier, says Kamath. “Someone that may have gotten cancer later, at age 65, is getting it at age 45,” he says. Younger People With Unexplained Symptoms May Benefit From a Second Opinion There is research showing that people in their twenties and thirties who are eventually diagnosed with cancer saw several doctors over the 6 to 12 months prior to their diagnosis, says Kamath. “And it wasn’t as if their symptoms really changed during that time. They were basically the same, but it ultimately took a different doctor coming across them to realize that something more serious was going on,” he says. Getting a second opinion and going to a hospital where there is more specialization and more awareness is important, says Kamath. “I think it takes a doctor really being educated on this to take that next step in terms of doing more testing to get to the bottom of what’s going on,” he says.